Jarosław Leszczyszyn

Author

Western University ORCID

Also Known As

J Leszczyszyn, J. Leszczyszyn, Jaroslaw Leszczyszyn, Jarosław Jerzy Leszczyszyn, Jarosław Leszczyszyn, Satoshi Komatsu

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Western University University of California San Diego Icahn School of Medicine at Mount Sinai Janssen (United States)Inserm

About

Jarosław Leszczyszyn is an author at Western University specializing in medicine, gastroenterology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1K
2	Gastroenterology	9	9	1K
3	Immunology	3	3	365
4	Public Health	2	2	40
5	Nutrition	1	1	12

Jarosław Leszczyszyn

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Bruce E. Sands, Peter M. Irving, Timothy Hoops, The Lancet ImmunologyClinical TrialsGastroenterologyMaintenance TherapyBiological Therapy	2022	277
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn, Gastroenterology InflammationAnti-inflammatoryControlled TrialGastroenterologySurgery	2021	216
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial Brian G. Feagan, Bruce E. Sands, William J. Sandborn, The Lancet. Gastroenterology & hepatology Systemic TreatmentGolimumab MonotherapyGastroenterologyPathologyUlcerative Colitis	2023	208
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin, Gastroenterology	2023	86
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study William J. Sandborn, Silvio Danese, Jarosław Leszczyszyn, Clinical Gastroenterology and Hepatology Gastrointestinal PharmacologyPhase 2BModerate-to-severe Ulcerative ColitisPharmacologyGastroenterology	2023	82
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Marc Ferrante, Geert D’Haens, Vipul Jairath, The Lancet Moderately-to-severely Active CrohnImmunologyGastroenterologyClinical GastroenterologyUlcerative Colitis	2024	76
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies David T. Rubin, Jessica R. Allegretti, Julián Panés, The Lancet Placebo-controlled InductionGastroenterologyPathologyClinical GastroenterologyGastrointestinal Pathology	2024	62
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial Silvio Danese, Remo Panaccione, Brian G. Feagan, The Lancet. Gastroenterology & hepatology UrologyMoxibustionGastroenterologyDouble-blind Galaxi-1 TrialMaintenance Results	2023	61
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis Bruce E. Sands, Brian G. Feagan, Laurent Peyrin‐Biroulet, New England Journal of Medicine	2024	56
Respiratory Function in Pregnant Women Lidia Hirnle, Hanna Gerber, Patrycja Leśnik, Advances in experimental medicine and biology GynecologyPregnancyMaternal HealthLung MechanicsPregnant Women	2013	28

Page 1